Skip to main content
. 2016 Nov 26;8(32):52225–52236. doi: 10.18632/oncotarget.13660

Figure 8. High levels of soluble LFA-3 in the serum of CLL patients are associated with poor overall survival.

Figure 8

(A) ELISA test of soluble LFA-3 (sLFA-3) in culture supernatants after 7 days of culture of healthy donor PBMC (n = 8) or CLL PBMC (n = 32). (B) ELISA test of sLFA-3 in sera from healthy donors (n = 9) or CLL patients (n = 71). (C) Kaplan-Meier curves showing the probability of overall survival from the first treatment. CLL patients were divided into two groups according to their sLFA-3 levels (cut-off = 16.7 ng/mL): low sLFA-3 (black) and high sLFA-3 (grey).